Middle East & Africa Pharmaceuticals Market Size and Forecast (2021 - 2031)
The pharmaceuticals market in the Middle East and Africa is poised for significant growth, with projections indicating that it will reach a value of approximately US$ 180.3 billion by 2031, up from US$ 115.0 billion in 2024. This growth trajectory reflects a compound annual growth rate (CAGR) of 6.7% from 2025 to 2031, driven by various factors that are reshaping the healthcare landscape in the region.
Market Overview
The Middle East and Africa pharmaceuticals market is categorized into several key regions, including the UAE, Saudi Arabia, South Africa, and other areas within the Middle East and Africa. The expansion of this market is largely attributed to advancements in healthcare infrastructure, an increasing demand for healthcare services, a rise in chronic diseases and cancers, supportive government policies, and collaborations with international pharmaceutical firms.
Chronic diseases such as diabetes, cardiovascular conditions, and cancer are on the rise in this region. The World Health Organization (WHO) has reported a significant increase in diabetes cases, particularly in Gulf Cooperation Council (GCC) countries like Saudi Arabia, the UAE, and Qatar. In Africa, diseases such as malaria, HIV/AIDS, and tuberculosis continue to pose substantial health challenges. The growing prevalence of these conditions is driving the demand for both generic and branded pharmaceutical products, creating ample opportunities for market growth.
Demographic Trends
The demographic landscape in the Middle East and Africa is also evolving, with a notable increase in the aging population, especially in Saudi Arabia and the UAE. As life expectancy rises, there is a corresponding increase in the demand for healthcare services and medications that address age-related health issues, including osteoporosis, Alzheimer's disease, and cardiovascular disorders. Although Africa has a younger median age, improvements in healthcare are leading to longer life expectancies, which in turn heightens the need for healthcare services. According to a 2021 report on aging in the MENA region, significant demographic shifts are expected by 2025, with the population aged over sixty-four projected to become the largest age group by 2050.
Market Segmentation
The Middle East and Africa pharmaceuticals market can be segmented based on various criteria:
The pharmaceutical industry in the region is experiencing annual growth of around 6%, primarily due to the increasing prevalence of chronic and severe health conditions. The global burden of diseases such as diabetes, obesity, cancer, and Alzheimer's is escalating, necessitating advancements in medical treatments. Current statistics indicate that there are approximately 171 billion diabetics worldwide, a number expected to double by 2030. Similarly, obesity affects around 1.4 billion individuals, with projections suggesting this could rise to 3.3 billion by 2030. Cancer remains a critical health issue, with significant rates of diagnosis among both men and women.
The COVID-19 pandemic has also had a profound impact on the pharmaceutical market, contributing an estimated US$ 500 billion in net cumulative growth from 2020 to 2027. While vaccination rates have improved, the inconsistent uptake of booster shots has created uncertainties regarding the pandemic's future trajectory. The demand for innovative drugs, particularly in oncology, is expected to surge, with spending projected to reach $370 billion by 2027. Specialty medicines are anticipated to account for 43% of global spending by 2027, with biotechnological advancements leading the way.
Country Insights
In terms of country-specific insights, Saudi Arabia stands out as the largest pharmaceuticals market in the Middle East, valued at US$ 12.1 billion in 2023. The country is rapidly advancing in biotechnology, aiming for self-sufficiency in vaccine production and biomanufacturing. The increasing healthcare needs, coupled with a rising prevalence of chronic diseases and government support for biotechnology, are driving market growth. The number of new cancer cases in Saudi Arabia is projected to rise significantly by 2040, highlighting the urgent need for innovative treatments.
As the population ages and healthcare infrastructure expands, the demand for pharmaceuticals is expected to grow substantially. Reports indicate that the elderly population in Saudi Arabia will increase significantly by 2050, necessitating healthcare solutions tailored to their unique needs. The government's commitment to enhancing healthcare services for older adults, along with increased healthcare expenditure, creates a favorable environment for the introduction of innovative therapies.
Conclusion
The Middle East and Africa pharmaceuticals market is on a robust growth path, driven by demographic changes, rising disease prevalence, and advancements in healthcare infrastructure. Key players in the market are focusing on innovation and strategic partnerships to meet the evolving healthcare needs of the region.
Market Overview
The Middle East and Africa pharmaceuticals market is categorized into several key regions, including the UAE, Saudi Arabia, South Africa, and other areas within the Middle East and Africa. The expansion of this market is largely attributed to advancements in healthcare infrastructure, an increasing demand for healthcare services, a rise in chronic diseases and cancers, supportive government policies, and collaborations with international pharmaceutical firms.
Chronic diseases such as diabetes, cardiovascular conditions, and cancer are on the rise in this region. The World Health Organization (WHO) has reported a significant increase in diabetes cases, particularly in Gulf Cooperation Council (GCC) countries like Saudi Arabia, the UAE, and Qatar. In Africa, diseases such as malaria, HIV/AIDS, and tuberculosis continue to pose substantial health challenges. The growing prevalence of these conditions is driving the demand for both generic and branded pharmaceutical products, creating ample opportunities for market growth.
Demographic Trends
The demographic landscape in the Middle East and Africa is also evolving, with a notable increase in the aging population, especially in Saudi Arabia and the UAE. As life expectancy rises, there is a corresponding increase in the demand for healthcare services and medications that address age-related health issues, including osteoporosis, Alzheimer's disease, and cardiovascular disorders. Although Africa has a younger median age, improvements in healthcare are leading to longer life expectancies, which in turn heightens the need for healthcare services. According to a 2021 report on aging in the MENA region, significant demographic shifts are expected by 2025, with the population aged over sixty-four projected to become the largest age group by 2050.
Market Segmentation
The Middle East and Africa pharmaceuticals market can be segmented based on various criteria:
- Molecule Type: The market is divided into Small Molecule and Biological/Biosimilar Products, with Small Molecule products holding the largest market share in 2024.
- Indication: The market is categorized into Metabolic Diseases, Cancer, Immunology, Respiratory Disorders, Cardiovascular Disorders, Neurology Disorders, Rare Diseases, and others, with Cancer leading the market share in 2024.
- Product Type: The market is split into Branded and Generic products, where Branded products dominate the market.
- Drug Type: The market includes Prescription and Over-the-Counter (OTC) drugs, with Prescription drugs holding the largest share.
- Distribution Channel: The market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies, with Hospital Pharmacies leading in market share.
The pharmaceutical industry in the region is experiencing annual growth of around 6%, primarily due to the increasing prevalence of chronic and severe health conditions. The global burden of diseases such as diabetes, obesity, cancer, and Alzheimer's is escalating, necessitating advancements in medical treatments. Current statistics indicate that there are approximately 171 billion diabetics worldwide, a number expected to double by 2030. Similarly, obesity affects around 1.4 billion individuals, with projections suggesting this could rise to 3.3 billion by 2030. Cancer remains a critical health issue, with significant rates of diagnosis among both men and women.
The COVID-19 pandemic has also had a profound impact on the pharmaceutical market, contributing an estimated US$ 500 billion in net cumulative growth from 2020 to 2027. While vaccination rates have improved, the inconsistent uptake of booster shots has created uncertainties regarding the pandemic's future trajectory. The demand for innovative drugs, particularly in oncology, is expected to surge, with spending projected to reach $370 billion by 2027. Specialty medicines are anticipated to account for 43% of global spending by 2027, with biotechnological advancements leading the way.
Country Insights
In terms of country-specific insights, Saudi Arabia stands out as the largest pharmaceuticals market in the Middle East, valued at US$ 12.1 billion in 2023. The country is rapidly advancing in biotechnology, aiming for self-sufficiency in vaccine production and biomanufacturing. The increasing healthcare needs, coupled with a rising prevalence of chronic diseases and government support for biotechnology, are driving market growth. The number of new cancer cases in Saudi Arabia is projected to rise significantly by 2040, highlighting the urgent need for innovative treatments.
As the population ages and healthcare infrastructure expands, the demand for pharmaceuticals is expected to grow substantially. Reports indicate that the elderly population in Saudi Arabia will increase significantly by 2050, necessitating healthcare solutions tailored to their unique needs. The government's commitment to enhancing healthcare services for older adults, along with increased healthcare expenditure, creates a favorable environment for the introduction of innovative therapies.
Conclusion
The Middle East and Africa pharmaceuticals market is on a robust growth path, driven by demographic changes, rising disease prevalence, and advancements in healthcare infrastructure. Key players in the market are focusing on innovation and strategic partnerships to meet the evolving healthcare needs of the region.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
3.3 Assumptions and Limitations
4. PHARMACEUTICAL MARKET LANDSCAPE
4.1 PEST Analysis
4.2 Regulatory Landscape
4.2.1 Middle East & Africa
4.2.1.1 Saudi Arabia
4.2.1.2 South Africa
4.2.1.3 United Arab Emirates (UAE)
4.3 List of Key Suppliers:
4.4 Average selling Price:
4.5 Sourcing Strategy:
4.6 Market Entry Barriers in the Global Pharmaceutical Market:
4.7 Top 10 Blockbuster Drugs Facing Patent Expiry in the Next 5 Years with Revenue Data and Market Impact:
5. MIDDLE EAST & AFRICA PHARMACEUTICAL MARKET – KEY MARKET DYNAMICS
5.1 Middle East & Africa Pharmaceutical Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Rising Global Disease Burden and Increasing Demand for Innovative Treatments
5.2.2 Expanding Global Access to Medicines and Growing Emerging Markets
5.3 Market Restraints
5.3.1 Regulatory Pressures and Market Shifts
5.4 Market Opportunities
5.4.1 Harnessing Innovation, AI, and Market Expansion
5.5 Future Trends
5.5.1 Regional Power Shifts, Supply Chain Diversification, and Regulatory Evolution
5.6 Impact of Drivers and Restraints:
6. PHARMACEUTICAL MARKET – MIDDLE EAST & AFRICA ANALYSIS
6.1 Middle East & Africa Pharmaceutical Market Revenue (US$ (US$ Billion)), 2021–2031
6.2 Middle East & Africa Pharmaceutical Market Forecast Analysis
7. MIDDLE EAST & AFRICA PHARMACEUTICAL MARKET ANALYSIS – BY MOLECULE TYPE
7.1 Small Molecule
7.1.1 Overview
7.1.2 Small Molecule: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
7.2 Biological and Biosimilar Products
7.2.1 Overview
7.2.2 Biological and Biosimilar Products: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
8. MIDDLE EAST & AFRICA PHARMACEUTICAL MARKET ANALYSIS – BY INDICATION
8.1 Metabolic Diseases
8.1.1 Overview
8.1.2 Metabolic Diseases: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
8.2 Cancer
8.2.1 Overview
8.2.2 Cancer: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
8.3 Immunology
8.3.1 Overview
8.3.2 Immunology: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
8.4 Respiratory Disorder
8.4.1 Overview
8.4.2 Respiratory Disorder: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
8.5 Cardiovascular Disorder
8.5.1 Overview
8.5.2 Cardiovascular Disorder: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
8.6 Neurology Disorder
8.6.1 Overview
8.6.2 Neurology Disorder: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
8.7 Rare Disease
8.7.1 Overview
8.7.2 Rare Disease: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
8.8 Others
8.8.1 Overview
8.8.2 Others: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
9. MIDDLE EAST & AFRICA PHARMACEUTICAL MARKET ANALYSIS – BY PRODUCT
9.1 Branded
9.1.1 Overview
9.1.2 Branded: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
9.2 Generic
9.2.1 Overview
9.2.2 Generic: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
10. MIDDLE EAST & AFRICA PHARMACEUTICAL MARKET ANALYSIS – BY TYPE
10.1 Prescription
10.1.1 Overview
10.1.2 Prescription: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
10.2 OTC Drugs
10.2.1 Overview
10.2.2 OTC Drugs: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
11. MIDDLE EAST & AFRICA PHARMACEUTICAL MARKET ANALYSIS – BY DISTRIBUTION CHANNEL
11.1 Hospital Pharmacies
11.1.1 Overview
11.1.2 Hospital Pharmacies: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
11.2 Retail Pharmacies
11.2.1 Overview
11.2.2 Retail Pharmacies: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
11.3 Online Pharmacies
11.3.1 Overview
11.3.2 Online Pharmacies: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
12. MIDDLE EAST & AFRICA PHARMACEUTICAL MARKET – COUNTRY ANALYSIS
12.1 Middle East & Africa
12.1.1 Middle East & Africa Pharmaceutical Market – Revenue and Forecast Analysis – by Country
12.1.1.1 Middle East & Africa Pharmaceutical Market – Revenue and Forecast Analysis – by Country
12.1.1.2 South Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
12.1.1.2.1 South Africa: Middle East & Africa Pharmaceutical Market Share – by Molecule Type
12.1.1.2.2 South Africa: Middle East & Africa Pharmaceutical Market Share – by Indication
12.1.1.2.3 South Africa: Middle East & Africa Pharmaceutical Market Share – by Product
12.1.1.2.4 South Africa: Middle East & Africa Pharmaceutical Market Share – by Type
12.1.1.2.5 South Africa: Middle East & Africa Pharmaceutical Market Share – by Distribution Channel
12.1.1.3 Saudi Arabia: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
12.1.1.3.1 Saudi Arabia: Middle East & Africa Pharmaceutical Market Share – by Molecule Type
12.1.1.3.2 Saudi Arabia: Middle East & Africa Pharmaceutical Market Share – by Indication
12.1.1.3.3 Saudi Arabia: Middle East & Africa Pharmaceutical Market Share – by Product
12.1.1.3.4 Saudi Arabia: Middle East & Africa Pharmaceutical Market Share – by Type
12.1.1.3.5 Saudi Arabia: Middle East & Africa Pharmaceutical Market Share – by Distribution Channel
12.1.1.4 United Arab Emirates: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
12.1.1.4.1 United Arab Emirates: Middle East & Africa Pharmaceutical Market Share – by Molecule Type
12.1.1.4.2 United Arab Emirates: Middle East & Africa Pharmaceutical Market Share – by Indication
12.1.1.4.3 United Arab Emirates: Middle East & Africa Pharmaceutical Market Share – by Product
12.1.1.4.4 United Arab Emirates: Middle East & Africa Pharmaceutical Market Share – by Type
12.1.1.4.5 United Arab Emirates: Middle East & Africa Pharmaceutical Market Share – by Distribution Channel
12.1.1.5 Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
12.1.1.5.1 Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market Share – by Molecule Type
12.1.1.5.2 Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market Share – by Indication
12.1.1.5.3 Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market Share – by Product
12.1.1.5.4 Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market Share – by Type
12.1.1.5.5 Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market Share – by Distribution Channel
13. COMPETITIVE LANDSCAPE
13.1 Company Market Share Analysis
14. INDUSTRY LANDSCAPE
14.1 Overview
14.2 Expansion
14.3 New Product Development
14.4 Merger and Acquisition
14.5 Partnerships
14.6 Other Business Strategies
15. COMPANY PROFILES
15.1 Johnson & Johnson
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 Pfizer Inc
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 Merck & Co Inc
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Eli Lilly and Co
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Financial Overview
15.4.4 SWOT Analysis
15.4.5 Key Developments
15.5 Bristol-Myers Squibb Co
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 ESTEVE
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 UCB SA
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 Teva Pharmaceutical Industries Ltd
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 Hikma Pharmaceuticals Plc
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 Viatris Inc
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments
15.11 AstraZeneca Plc
15.11.1 1Key Facts
15.11.2 Business Description
15.11.3 Products and Services
15.11.4 Financial Overview
15.11.5 SWOT Analysis
15.11.6 Key Developments
15.12 Sanofi SA
15.12.1 Key Facts
15.12.2 Business Description
15.12.3 Products and Services
15.12.4 Financial Overview
15.12.5 SWOT Analysis
15.12.6 Key Developments
15.13 GSK Plc
15.13.1 Key Facts
15.13.2 Business Description
15.13.3 Products and Services
15.13.4 Financial Overview
15.13.5 SWOT Analysis
15.13.6 Key Developments
15.14 F. Hoffmann-La Roche Ltd
15.14.1 Key Facts
15.14.2 Business Description
15.14.3 Products and Services
15.14.4 Financial Overview
15.14.5 SWOT Analysis
15.14.6 Key Developments
15.15 Novartis AG
15.15.1 Key Facts
15.15.2 Business Description
15.15.3 Products and Services
15.15.4 Financial Overview
15.15.5 SWOT Analysis
15.15.6 Key Developments
15.16 AbbVie Inc
15.16.1 Key Facts
15.16.2 Business Description
15.16.3 Products and Services
15.16.4 Financial Overview
15.16.5 SWOT Analysis
15.16.6 Key Developments
16. APPENDIX
16.1 Glossary of Terms
16.2 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
3.3 Assumptions and Limitations
4. PHARMACEUTICAL MARKET LANDSCAPE
4.1 PEST Analysis
4.2 Regulatory Landscape
4.2.1 Middle East & Africa
4.2.1.1 Saudi Arabia
4.2.1.2 South Africa
4.2.1.3 United Arab Emirates (UAE)
4.3 List of Key Suppliers:
4.4 Average selling Price:
4.5 Sourcing Strategy:
4.6 Market Entry Barriers in the Global Pharmaceutical Market:
4.7 Top 10 Blockbuster Drugs Facing Patent Expiry in the Next 5 Years with Revenue Data and Market Impact:
5. MIDDLE EAST & AFRICA PHARMACEUTICAL MARKET – KEY MARKET DYNAMICS
5.1 Middle East & Africa Pharmaceutical Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Rising Global Disease Burden and Increasing Demand for Innovative Treatments
5.2.2 Expanding Global Access to Medicines and Growing Emerging Markets
5.3 Market Restraints
5.3.1 Regulatory Pressures and Market Shifts
5.4 Market Opportunities
5.4.1 Harnessing Innovation, AI, and Market Expansion
5.5 Future Trends
5.5.1 Regional Power Shifts, Supply Chain Diversification, and Regulatory Evolution
5.6 Impact of Drivers and Restraints:
6. PHARMACEUTICAL MARKET – MIDDLE EAST & AFRICA ANALYSIS
6.1 Middle East & Africa Pharmaceutical Market Revenue (US$ (US$ Billion)), 2021–2031
6.2 Middle East & Africa Pharmaceutical Market Forecast Analysis
7. MIDDLE EAST & AFRICA PHARMACEUTICAL MARKET ANALYSIS – BY MOLECULE TYPE
7.1 Small Molecule
7.1.1 Overview
7.1.2 Small Molecule: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
7.2 Biological and Biosimilar Products
7.2.1 Overview
7.2.2 Biological and Biosimilar Products: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
8. MIDDLE EAST & AFRICA PHARMACEUTICAL MARKET ANALYSIS – BY INDICATION
8.1 Metabolic Diseases
8.1.1 Overview
8.1.2 Metabolic Diseases: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
8.2 Cancer
8.2.1 Overview
8.2.2 Cancer: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
8.3 Immunology
8.3.1 Overview
8.3.2 Immunology: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
8.4 Respiratory Disorder
8.4.1 Overview
8.4.2 Respiratory Disorder: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
8.5 Cardiovascular Disorder
8.5.1 Overview
8.5.2 Cardiovascular Disorder: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
8.6 Neurology Disorder
8.6.1 Overview
8.6.2 Neurology Disorder: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
8.7 Rare Disease
8.7.1 Overview
8.7.2 Rare Disease: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
8.8 Others
8.8.1 Overview
8.8.2 Others: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
9. MIDDLE EAST & AFRICA PHARMACEUTICAL MARKET ANALYSIS – BY PRODUCT
9.1 Branded
9.1.1 Overview
9.1.2 Branded: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
9.2 Generic
9.2.1 Overview
9.2.2 Generic: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
10. MIDDLE EAST & AFRICA PHARMACEUTICAL MARKET ANALYSIS – BY TYPE
10.1 Prescription
10.1.1 Overview
10.1.2 Prescription: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
10.2 OTC Drugs
10.2.1 Overview
10.2.2 OTC Drugs: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
11. MIDDLE EAST & AFRICA PHARMACEUTICAL MARKET ANALYSIS – BY DISTRIBUTION CHANNEL
11.1 Hospital Pharmacies
11.1.1 Overview
11.1.2 Hospital Pharmacies: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
11.2 Retail Pharmacies
11.2.1 Overview
11.2.2 Retail Pharmacies: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
11.3 Online Pharmacies
11.3.1 Overview
11.3.2 Online Pharmacies: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
12. MIDDLE EAST & AFRICA PHARMACEUTICAL MARKET – COUNTRY ANALYSIS
12.1 Middle East & Africa
12.1.1 Middle East & Africa Pharmaceutical Market – Revenue and Forecast Analysis – by Country
12.1.1.1 Middle East & Africa Pharmaceutical Market – Revenue and Forecast Analysis – by Country
12.1.1.2 South Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
12.1.1.2.1 South Africa: Middle East & Africa Pharmaceutical Market Share – by Molecule Type
12.1.1.2.2 South Africa: Middle East & Africa Pharmaceutical Market Share – by Indication
12.1.1.2.3 South Africa: Middle East & Africa Pharmaceutical Market Share – by Product
12.1.1.2.4 South Africa: Middle East & Africa Pharmaceutical Market Share – by Type
12.1.1.2.5 South Africa: Middle East & Africa Pharmaceutical Market Share – by Distribution Channel
12.1.1.3 Saudi Arabia: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
12.1.1.3.1 Saudi Arabia: Middle East & Africa Pharmaceutical Market Share – by Molecule Type
12.1.1.3.2 Saudi Arabia: Middle East & Africa Pharmaceutical Market Share – by Indication
12.1.1.3.3 Saudi Arabia: Middle East & Africa Pharmaceutical Market Share – by Product
12.1.1.3.4 Saudi Arabia: Middle East & Africa Pharmaceutical Market Share – by Type
12.1.1.3.5 Saudi Arabia: Middle East & Africa Pharmaceutical Market Share – by Distribution Channel
12.1.1.4 United Arab Emirates: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
12.1.1.4.1 United Arab Emirates: Middle East & Africa Pharmaceutical Market Share – by Molecule Type
12.1.1.4.2 United Arab Emirates: Middle East & Africa Pharmaceutical Market Share – by Indication
12.1.1.4.3 United Arab Emirates: Middle East & Africa Pharmaceutical Market Share – by Product
12.1.1.4.4 United Arab Emirates: Middle East & Africa Pharmaceutical Market Share – by Type
12.1.1.4.5 United Arab Emirates: Middle East & Africa Pharmaceutical Market Share – by Distribution Channel
12.1.1.5 Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
12.1.1.5.1 Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market Share – by Molecule Type
12.1.1.5.2 Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market Share – by Indication
12.1.1.5.3 Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market Share – by Product
12.1.1.5.4 Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market Share – by Type
12.1.1.5.5 Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market Share – by Distribution Channel
13. COMPETITIVE LANDSCAPE
13.1 Company Market Share Analysis
14. INDUSTRY LANDSCAPE
14.1 Overview
14.2 Expansion
14.3 New Product Development
14.4 Merger and Acquisition
14.5 Partnerships
14.6 Other Business Strategies
15. COMPANY PROFILES
15.1 Johnson & Johnson
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 Pfizer Inc
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 Merck & Co Inc
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Eli Lilly and Co
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Financial Overview
15.4.4 SWOT Analysis
15.4.5 Key Developments
15.5 Bristol-Myers Squibb Co
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 ESTEVE
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 UCB SA
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 Teva Pharmaceutical Industries Ltd
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 Hikma Pharmaceuticals Plc
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 Viatris Inc
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments
15.11 AstraZeneca Plc
15.11.1 1Key Facts
15.11.2 Business Description
15.11.3 Products and Services
15.11.4 Financial Overview
15.11.5 SWOT Analysis
15.11.6 Key Developments
15.12 Sanofi SA
15.12.1 Key Facts
15.12.2 Business Description
15.12.3 Products and Services
15.12.4 Financial Overview
15.12.5 SWOT Analysis
15.12.6 Key Developments
15.13 GSK Plc
15.13.1 Key Facts
15.13.2 Business Description
15.13.3 Products and Services
15.13.4 Financial Overview
15.13.5 SWOT Analysis
15.13.6 Key Developments
15.14 F. Hoffmann-La Roche Ltd
15.14.1 Key Facts
15.14.2 Business Description
15.14.3 Products and Services
15.14.4 Financial Overview
15.14.5 SWOT Analysis
15.14.6 Key Developments
15.15 Novartis AG
15.15.1 Key Facts
15.15.2 Business Description
15.15.3 Products and Services
15.15.4 Financial Overview
15.15.5 SWOT Analysis
15.15.6 Key Developments
15.16 AbbVie Inc
15.16.1 Key Facts
15.16.2 Business Description
15.16.3 Products and Services
15.16.4 Financial Overview
15.16.5 SWOT Analysis
15.16.6 Key Developments
16. APPENDIX
16.1 Glossary of Terms
16.2 About The Insight Partners
LIST OF TABLES
Table 1. Middle East & Africa Pharmaceutical Market Segmentation
Table 2. Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Table 3. Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion)) – by Molecule Type
Table 4. Table: Top-Selling Drugs in 2021
Table 5. Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion)) – by Indication
Table 6. Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion)) – by Product
Table 7. Key brands facing patent expirations
Table 8. Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion)) – by Type
Table 9. Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion)) – by Distribution Channel
Table 10. Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion)) – by Country
Table 11. South Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Molecule Type
Table 12. South Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Indication
Table 13. South Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Product
Table 14. South Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Type
Table 15. South Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Distribution Channel
Table 16. Saudi Arabia: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Molecule Type
Table 17. Saudi Arabia: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Indication
Table 18. Saudi Arabia: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Product
Table 19. Saudi Arabia: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Type
Table 20. Saudi Arabia: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Distribution Channel
Table 21. United Arab Emirates: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Molecule Type
Table 22. United Arab Emirates: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Indication
Table 23. United Arab Emirates: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Product
Table 24. United Arab Emirates: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Type
Table 25. United Arab Emirates: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Distribution Channel
Table 26. Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Molecule Type
Table 27. Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Indication
Table 28. Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Product
Table 29. Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Type
Table 30. Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Distribution Channel
Table 31. Company Market Share Analysis
Table 32. Glossary of Terms, Pharmaceutical Market
Table 1. Middle East & Africa Pharmaceutical Market Segmentation
Table 2. Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Table 3. Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion)) – by Molecule Type
Table 4. Table: Top-Selling Drugs in 2021
Table 5. Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion)) – by Indication
Table 6. Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion)) – by Product
Table 7. Key brands facing patent expirations
Table 8. Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion)) – by Type
Table 9. Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion)) – by Distribution Channel
Table 10. Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion)) – by Country
Table 11. South Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Molecule Type
Table 12. South Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Indication
Table 13. South Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Product
Table 14. South Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Type
Table 15. South Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Distribution Channel
Table 16. Saudi Arabia: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Molecule Type
Table 17. Saudi Arabia: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Indication
Table 18. Saudi Arabia: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Product
Table 19. Saudi Arabia: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Type
Table 20. Saudi Arabia: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Distribution Channel
Table 21. United Arab Emirates: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Molecule Type
Table 22. United Arab Emirates: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Indication
Table 23. United Arab Emirates: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Product
Table 24. United Arab Emirates: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Type
Table 25. United Arab Emirates: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Distribution Channel
Table 26. Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Molecule Type
Table 27. Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Indication
Table 28. Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Product
Table 29. Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Type
Table 30. Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ (US$ Billion)) – by Distribution Channel
Table 31. Company Market Share Analysis
Table 32. Glossary of Terms, Pharmaceutical Market
LIST OF FIGURES
Figure 1. Middle East & Africa Pharmaceutical Market Segmentation – Country
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Middle East & Africa Pharmaceutical Market Revenue (US$ (US$ Billion)), 2021–2031
Figure 5. Middle East & Africa Pharmaceutical Market Share (%) – by Molecule Type (2024 and 2031)
Figure 6. Small Molecule: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 7. Biological and Biosimilar Products: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 8. Middle East & Africa Pharmaceutical Market Share (%) – by Indication (2024 and 2031)
Figure 9. Metabolic Diseases: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 10. Cancer: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 11. Immunology: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 12. Respiratory Disorder: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 13. Cardiovascular Disorder: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 14. Neurology Disorder: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 15. Rare Disease: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 16. Others: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 17. Middle East & Africa Pharmaceutical Market Share (%) – by Product (2024 and 2031)
Figure 18. Branded: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 19. Generic: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 20. Middle East & Africa Pharmaceutical Market Share (%) – by Type (2024 and 2031)
Figure 21. Prescription: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 22. OTC Drugs: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 23. Middle East & Africa Pharmaceutical Market Share (%) – by Distribution Channel (2024 and 2031)
Figure 24. Hospital Pharmacies: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 25. Retail Pharmacies: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 26. Online Pharmacies: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 27. Middle East & Africa Pharmaceutical Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 28. South Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ (US$ Billion))
Figure 29. Saudi Arabia: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ (US$ Billion))
Figure 30. United Arab Emirates: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ (US$ Billion))
Figure 31. Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ (US$ Billion))
Figure 1. Middle East & Africa Pharmaceutical Market Segmentation – Country
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Middle East & Africa Pharmaceutical Market Revenue (US$ (US$ Billion)), 2021–2031
Figure 5. Middle East & Africa Pharmaceutical Market Share (%) – by Molecule Type (2024 and 2031)
Figure 6. Small Molecule: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 7. Biological and Biosimilar Products: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 8. Middle East & Africa Pharmaceutical Market Share (%) – by Indication (2024 and 2031)
Figure 9. Metabolic Diseases: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 10. Cancer: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 11. Immunology: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 12. Respiratory Disorder: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 13. Cardiovascular Disorder: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 14. Neurology Disorder: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 15. Rare Disease: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 16. Others: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 17. Middle East & Africa Pharmaceutical Market Share (%) – by Product (2024 and 2031)
Figure 18. Branded: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 19. Generic: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 20. Middle East & Africa Pharmaceutical Market Share (%) – by Type (2024 and 2031)
Figure 21. Prescription: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 22. OTC Drugs: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 23. Middle East & Africa Pharmaceutical Market Share (%) – by Distribution Channel (2024 and 2031)
Figure 24. Hospital Pharmacies: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 25. Retail Pharmacies: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 26. Online Pharmacies: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ (US$ Billion))
Figure 27. Middle East & Africa Pharmaceutical Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 28. South Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ (US$ Billion))
Figure 29. Saudi Arabia: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ (US$ Billion))
Figure 30. United Arab Emirates: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ (US$ Billion))
Figure 31. Rest of Middle East & Africa: Middle East & Africa Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ (US$ Billion))
